# Iovance Biotherapeutics share price today (Iovance Biotherapeutics, Inc., IOVA)

> Iovance Biotherapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. IOVA · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/iova

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $7.74 (+236.5% in a year)
- Revenue (Jun 2026): $99.3 M (+65.7% on a year ago)
- Profit (Jun 2026): −$47.3 M
- Operating margin: −52.3% (+137.5 points on a year ago)
- ROE: −56%, FY25
- ROIC: −18.7%, against a 8.7% cost of capital: −27.4 points

Biggest thing to watch: the price has already been rising for 22 weeks, so timing is the risk more than the business. ## What is the Iovance Biotherapeutics share price today? Iovance Biotherapeutics, Inc.'s share price was $7.74 at the close on 5 November 2026. It has been rising for 22 weeks. That is 29.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $2 and $15, and at that close it sat 45% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 20 weeks in a row. Over the last 10 years the share price moved −10% while the S&P 500 moved +245%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Iovance Biotherapeutics pay? Iovance Biotherapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Iovance Biotherapeutics on? Iovance Biotherapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Iovance Biotherapeutics profitable? Iovance Biotherapeutics, Inc. posted a net loss of $47.3 M in the Jun 2026 quarter. The full FY25 year was a loss of $391 M. That loss is 47.6% of the quarter's revenue. The same quarter a year earlier lost $112 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Iovance Biotherapeutics make, and is it growing? Iovance Biotherapeutics, Inc. reported $99.3 M of revenue in the Jun 2026 quarter, +65.7% on the same quarter a year earlier. That is the 9th quarter in a row with growth on the year before. Over 2 years it has grown 1,388.7% a year on average. The last full year, FY25, came in at $264 M. The last four reported quarters add to $325 M. FY25 revenue was $264 M, +60.6% on the year before. Recent pace: the last four quarters grew +35.8% on average, against 1,388.7% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +34.5%, against +214.9% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Iovance Biotherapeutics keep? Iovance Biotherapeutics, Inc.'s operating margin was −52.3% in the Jun 2026 quarter, 137.5 percentage points higher than the same quarter a year ago. Across 3 years it has been between −38,735.0% and −151.1%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +137.5 percentage points on the year while gross margin changed +37.6 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Iovance Biotherapeutics' profit turning into cash? Iovance Biotherapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $302 M of cash, against −$391 M of profit. After $33.8 M of spending on assets, free cash was −$336 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Iovance Biotherapeutics' cash go? Iovance Biotherapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $67.2 M on assets over the last 3 years. Averaged over those years that is 8.5% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $67.2 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Iovance Biotherapeutics' P/E ratio, and how does it compare with its own history? Iovance Biotherapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Iovance Biotherapeutics, Inc. at 13.3× its FY25 revenue of $264 M. The P/E comes back here once profit turns positive. ## Is the Iovance Biotherapeutics business getting better or worse? Iovance Biotherapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Iovance Biotherapeutics earn on its capital? Iovance Biotherapeutics, Inc. earned a ROE of −56% in FY25. That is up from a low of −76% in FY23. Its return on capital used (ROIC) is 27.4 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −148.4% net margin and 0.29× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −148.4% net margin × 0.29× asset turnover × 1.31× leverage (assets divided by equity) ≈ −56.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −18.7% − 8.7% = −27.4 percentage points. The 8.7% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Iovance Biotherapeutics have too much debt? Iovance Biotherapeutics, Inc. has total debt of $46.0 M against shareholder equity of $736 M as of Jun 2026, so its debt is 0.06× its equity, which is very little. Year by year, that ratio went from 0.12 in FY21 to 0.07 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Iovance Biotherapeutics shareholding pattern? 14.9% of Iovance Biotherapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 3.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Iovance Biotherapeutics from balance-sheet trouble? For Iovance Biotherapeutics, Inc., the Z-score is −0.81. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −0.81 is inside the danger zone, so the balance sheet is a real risk. ## How does Iovance Biotherapeutics rank in its industry? There is no score against its industry: Iovance Biotherapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Iovance Biotherapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Iovance Biotherapeutics in size? Iovance Biotherapeutics is the 54th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Xenon Pharmaceuticals Inc., AbCellera Biologics Inc. and Tango Therapeutics, Inc. Just below it: Arcutis Biotherapeutics, Inc., Telix Pharmaceuticals and Tarsus Pharmaceuticals, Inc. ### Biotechnology companies close in size

1. [Xenon Pharmaceuticals Inc.](https://www.sectoralpha.in/us/stocks/xene) $3.6 billion
2. [AbCellera Biologics Inc.](https://www.sectoralpha.in/us/stocks/abcl) $3.6 billion
3. [Tango Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/tngx) $3.5 billion
4. Iovance Biotherapeutics, Inc. $3.5 billion
5. [Arcutis Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/arqt) $3.4 billion
6. [Telix Pharmaceuticals Limited](https://www.sectoralpha.in/us/stocks/tlx) $3.3 billion
7. [Tarsus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/tars) $3.3 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Neptune Insurance Holdings Inc.](https://www.sectoralpha.in/us/stocks/np) $3.9 billion · Insurance Brokers
2. [Manchester United plc](https://www.sectoralpha.in/us/stocks/manu) $3.9 billion · Entertainment
3. Iovance Biotherapeutics, Inc. $3.9 billion
4. [Marriott Vacations Worldwide Corporation](https://www.sectoralpha.in/us/stocks/vac) $3.9 billion · Resorts & Casinos
5. [Comstock Resources, Inc.](https://www.sectoralpha.in/us/stocks/crk) $3.9 billion · Oil & Gas Exploration & Production

## What else do people ask about Iovance Biotherapeutics? ### What were Iovance Biotherapeutics's latest quarterly results? Iovance Biotherapeutics, Inc. reported revenue of $99.3 M and a net loss of $47.3 M for the Jun 2026 quarter. Earnings per share were −$0.11. The operating margin was −52.3%, 137.5 percentage points higher than a year earlier (as of 5 November 2026). ### What is Iovance Biotherapeutics's market cap? Iovance Biotherapeutics, Inc.'s market capitalisation is $3.5 B at a stock price of $7.74. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Iovance Biotherapeutics performing? Iovance Biotherapeutics, Inc.'s share price has been rising for 22 weeks. Over the past 13 weeks it has done better than the S&P 500, for 20 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Iovance Biotherapeutics's stock price go up? This page does not forecast Iovance Biotherapeutics, Inc.'s stock price. What it shows instead: the stock price is $7.74, and it has been rising for 22 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Where is Iovance Biotherapeutics in its business cycle? Iovance Biotherapeutics, Inc.'s FY25 operating margin was −151.1%, against a 3-year range of −38,735.0% to −151.1%: the middle of its own range, neither a peak nor a low. The latest quarter was −52.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Iovance Biotherapeutics story? Biggest thing to watch: the price has already been rising for 22 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Iovance Biotherapeutics a stock worth studying right now? What the numbers show: Iovance Biotherapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.